Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.
Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.
Medincell Capex-to-Operating-Income Related Terms
Medincell Capex-to-Operating-Income Historical Data
* Premium members only.
The historical data trend for Medincell's Capex-to-Operating-Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDCLF vs VRTX, REGN, ALNY: Capex-to-Operating-Income Comparison
For the Biotechnology subindustry, Medincell's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medincell Capex-to-Operating-Income vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medincell's Capex-to-Operating-Income distribution charts can be found below:
* The bar in red indicates where Medincell's Capex-to-Operating-Income falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Capex-to-Operating-Income of 0.00 mean?
Medincell (MDCLF) has a Capex-to-Operating-Income of 0.00 as of Mar. 2026. Capex to Operating Income ratio measures a company's investments in physical assets to its operating income. View historical data on Medincell and its competitors. According to the industry distribution chart, Medincell ranks #999999 out of 208 companies in the Biotechnology industry.
Is Medincell's Capex-to-Operating-Income too high?
Medincell's current Capex-to-Operating-Income is 0.00. Based on the distribution chart, Medincell ranks #999999 out of 208 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Medincell has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Medincell's Capex-to-Operating-Income compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medincell ranks #999999 out of 208 companies for Capex-to-Operating-Income. This places Medincell in the lower half of its industry. The industry median Capex-to-Operating-Income is 0.38. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Capex-to-Operating-Income for a Biotechnology company?
The median Capex-to-Operating-Income among Biotechnology companies is 0.38, based on 208 companies in the industry. Companies in the top quartile (top 25%) have a Capex-to-Operating-Income significantly above this median, while those in the bottom quartile fall well below. However, Capex-to-Operating-Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Capex-to-Operating-Income mean?
A high Capex-to-Operating-Income can signal that a stock is expensive relative to its fundamentals. Capex to Operating Income ratio measures a company's investments in physical assets to its operating income. View historical data on Medincell and its competitors. For the Biotechnology industry, the median Capex-to-Operating-Income is 0.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medincell's current Capex-to-Operating-Income is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medincell stock overvalued right now?
Medincell (MDCLF) has a current Capex-to-Operating-Income of 0.00. The stock's GF Value™ is $27.51, compared to a current price of $34.39 — trading 25% above its estimated fair value. The current Capex-to-Operating-Income is 0.00. Medincell's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Capex-to-Operating-Income calculated?
Capex-to-Operating-Income is calculated from a company's financial statements. For Medincell (MDCLF), the current Capex-to-Operating-Income is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medincell (MDCLF) Overvalued in 2026?
Based on GuruFocus' analysis, Medincell stock appears to be overvalued.
The current stock price of $34.39 is trading 25% above its estimated GF Value™ of $27.51.
Key valuation signals for MDCLF:
Capex-to-Operating-Income: 0.00
GF Value™: $27.51 vs. price of $34.39 (25% above fair value)
No single metric tells the full story. See the MDCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.
77GF Score
Get the complete analysis for MDCLF
Capex-to-Operating-Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDCLF has been successfully added to your 
